Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

NCT04790448 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: Cetuximab
DRUG: Irinotecan
DRUG: Vemurafenib

Sponsor

Sun Yat-sen University